High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis

Ofir Elalouf1 Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence[email protected]

Merav Lidar2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;3 Rheumatology Unit, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel

Tatiana Reitblat4 Rheumatology Unit, Barzilai Medical Center, Ashkelon, Israel

Devy Zisman5 Department of Rheumatology, Carmel Medical Center, Haifa, Israel

Alexandra Balbir-Gurman6 Rheumatology Institute

Odelia Hakakian1 Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Tanya Mashiach7 Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel

Ronit Almog7 Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel

Ori Elkayam1 Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel;2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

show all

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis

Articles from other publishers (1)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis

Citations (1)

Articles from other publishers (1)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date